1-8 of 8
Mark Yan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Gilles Salles, Franck Morschhauser, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný, Georg Lenz, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Graham P. Collins, Yuqin Song, Antonio Pinto, Shinya Rai, Koji Izutsu, Calvin Lee, Saibah Chohan, Matthew Sugidono, Yanwen Jiang, Connie Lee Batlevi, Mark Yan, Jamie Hirata, Hervé Tilly, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 469.
https://doi.org/10.1182/blood-2024-197938
Published: 2024
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6623–6626.
https://doi.org/10.1182/blood-2022-157761
Published: 2022
Journal Articles

CO43923: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatment Combinations in Patients with Multiple Myeloma

Semira Sheikh, Upen Patil, Kristin Wehrman, Elissavet Sideri, Shannon M. Ruppert, Yanke Yu, Mark Yan, Jasdeep Bhatti, Lydia Pogeza, Yann Nouet
Journal: Blood
Blood (2022) 140 (Supplement 1): 12640–12641.
https://doi.org/10.1182/blood-2022-157737
Published: 2022
Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan Miguel Bergua Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta Costa, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2021-154729
Published: 2021
Journal Articles

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Mark Yan, Yi Meng Chang, Vibha Raghavan, Estella Dong, Christian Klein, PhD, Tina G Nielsen, Joseph N Paulson, Katerina Hatzi
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-134867
Published: 2020
Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1907.
https://doi.org/10.1182/blood-2019-123652
Published: 2019
Journal Articles

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Aaron T. Gerds, MDMS, Bart L Scott, MD, Peter L Greenberg, MD, Samer K. Khaled, MD, Tara L Lin, MD, Daniel A Pollyea, MD, Amit Verma, MD, Monique Dail, Cherie Green, Connie Ma, Bruno C Medeiros, Patrick Phuong, Michael Wenger, Mark Yan, William B. Donnellan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 466.
https://doi.org/10.1182/blood-2018-99-118577
Published: 2018
Journal Articles

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Cherie Green, Mark Yan, Stefani Nalle, Connie Ma, Alberto Robert, Judy Zhong, Kartik Krishnan, Patrick Phuong, PharmD, John Byon, Paul Woodard, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD, Joanne I. Adamkewicz, Jeffrey M. Venstrom, Monique Dail
Journal: Blood
Blood (2017) 130 (Supplement 1): 4241.
https://doi.org/10.1182/blood.V130.Suppl_1.4241.4241
Published: 2017